Spinocerebellar Ataxia Type 2 Presenting With Cognitive Regression in Childhood

Abstract

Spinocerebellar ataxia type 2 typically presents in adulthood with progressive ataxia, dysarthria, tremor, and slow saccadic eye movements. Childhood-onset spinocerebellar ataxia type 2 is rare, and only the infantile-onset form has been well characterized clinically. This article describes a girl who met all developmental milestones until age 3½ years, when she experienced cognitive regression that preceded motor regression by 6 months. A diagnosis of spinocerebellar ataxia type 2 was delayed until she presented to the emergency department at age 7 years. This report documents the results of her neuropsychologic evaluation at both time points. This case broadens the spectrum of spinocerebellar ataxia type 2 presentation in childhood, highlights the importance of considering a spinocerebellar ataxia in a child who presents with cognitive regression only, and extends currently available clinical information to help clinicians discuss the prognosis in childhood spinocerebellar ataxia type 2.

Keywords

spinocerebellar ataxia cognitive regression

Get full access to this article

View all access options for this article.

References

Gispert S. , Twells R. , Orozco G. , et al. Chromosomal assignment of the second locus for autosomal dominant cerebellar ataxia (SCA2) to chromosome 12q23-24.1. Nat Genet. 1993;4:295-299.

Orozco Diaz G. , Nodarse Fleites A. , Cordoves Sagaz R. , Auburger G. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguin, Cuba. Neurology. 1990;40:1369-1375.

Orozco G. , Estrada R. , Perry TL , et al. Dominantly inherited olivopontocerebellar atrophy from eastern Cuba. Clinical, neuropathological, and biochemical findings. J Neurol Sci. 1989;93:37-50.

Durr A. , Smadja D. , Cancel G. , et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain. 1995 ;118:1573-1581.

Babovic-Vuksanovic D. , Snow K. , Patterson MC , Michels VV Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion. Am J Med Genet. 1998;79:383-387.

Mao R. , Aylsworth AS , Potter N. , et al. Childhood-onset ataxia: testing for large CAG-repeats in SCA2 and SCA7. Am J Med Genet. 2002;110:338-345.

Moretti P. , Blazo M. , Garcia L. , et al. Spinocerebellar ataxia type 2 (SCA2) presenting with ophthalmoplegia and developmental delay in infancy. Am J Med Genet A. 2004;124:392-396.

Riess O. , Laccone FA , Gispert S. , et al. SCA2 trinucleotide expansion in German SCA patients. Neurogenetics. 1997;1:59-64.

Cancel G. , Durr A. , Didierjean O. , et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet. 1997;6:709-715.

10.

Dirik E. , Yis U. , Basak N. , Soydan E. , Hudaoglu O. , Ozgonul F. Spinocerebellar ataxia type 2 in a Turkish family. J Child Neurol. 2007;22:891-894.

11.

Geschwind DH , Perlman S. , Figueroa CP , Treiman LJ , Pulst SM The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet. 1997; 60:842-850.

12.

Cancel G. , Stevanin G. , Durr A. , et al. SCA2 is not a major locus for ADCA type I in French families . Am J Med Genet. 1995; 60:382-385.

13.

Watase K. , Gatchel JR , Sun Y. , et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007;4:e182.

14.

Gardian G. , Browne SE , Choi DK , et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem. 2005;280:556-563.

15.

Ferrante RJ , Kubilus JK , Lee J. , et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003 ;23:9418-9427.

16.

Hockly E. , Richon VM , Woodman B. , et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2003;100:2041-2046.